About Pharvaris
Pharvaris is a company based in Leiden (Netherlands) founded in 2015 by Berndt Modig. Pharvaris has raised $164.21 million across 3 funding rounds from investors including General Atlantic, Idinvest Partners and Kurma Partners. The company has 108 employees as of December 31, 2024. Pharvaris offers products and services including Deucrictibant. Pharvaris operates in a competitive market with competitors including Ultragenyx, Alnylam, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Leiden, Netherlands
- Employees 108 as on 31 Dec, 2024
- Founders Berndt Modig
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pharvaris N.V.
-
Annual Revenue
Not available
-
Net Profit
-$145.19 M (USD)-33.13as on Dec 31, 2024
-
EBITDA
-$157.3 M (USD)-50.53as on Dec 31, 2024
-
Total Equity Funding
$164.21 M (USD)
in 3 rounds
-
Latest Funding Round
$80 M (USD), Series C
Nov 18, 2020
-
Investors
General Atlantic
& 8 more
-
Employee Count
108
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pharvaris
Pharvaris is a publicly listed company on the NASDAQ with ticker symbol PHVS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Pharvaris
Pharvaris offers a comprehensive portfolio of products and services, including Deucrictibant.
Medication for preventing and treating HAE attacks effectively
People of Pharvaris
Unlock access to complete
Unlock access to complete
Leadership Team
16 people
Software Development Team
5 people
Product Management Team
4 people
Human Resources and Administration
3 people
Finance and Accounting
3 people
Head Team
2 people
Sales and Marketing
2 people
Data Analysis and Operations Team
2 people
Unlock access to complete
Funding Insights of Pharvaris
Pharvaris has successfully raised a total of $164.21M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pharvaris
Pharvaris has secured backing from 9 investors, including venture fund investors. Prominent investors backing the company include General Atlantic, Idinvest Partners and Kurma Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Private equity fund focused on global markets
|
Locked | Locked | Locked | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked |
Investor details for Pharvaris
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pharvaris
Investment portfolio details for Pharvaris
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pharvaris
Detailed financials for Pharvaris
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pharvaris Comparisons
Peer comparison for Pharvaris
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pharvaris
Pharvaris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ultragenyx, Alnylam, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
B cells are programmed as biofactories for therapeutic protein delivery.
|
Detailed competitors of Pharvaris
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pharvaris
Complete news archive for Pharvaris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pharvaris
Pharvaris was founded in 2015.
Pharvaris is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Berndt Modig is the current CEO of Pharvaris. They have also founded this company.
Pharvaris is a funded company, having raised a total of $164.21M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Pharvaris is 108.
Pharvaris was founded in 2015 and is based in Leiden, Netherlands. As a preclinical-stage biopharmaceutical company, focus is placed on developing oral therapies for hereditary angioedema. The lead candidate, PHA121, functions as a bradykinin B2 receptor competitive antagonist and has shown activity in relevant disease models. Advancement of this molecule into IND-enabling studies is underway. Operations center on bradykinin-mediated conditions within the rare disease sector.
Pharvaris's top competitors include Alnylam, BioMarin Pharmaceutical and Ultragenyx.
Pharvaris offers Deucrictibant.
Yes, Pharvaris is publicly traded on NASDAQ under the ticker symbol PHVS.
Pharvaris has 9 investors. Key investors include General Atlantic, Idinvest Partners, Kurma Partners, Life Sciences Partners, and Viking Capital.
The ticker symbol of Pharvaris is PHVS on NASDAQ.